Giants of Cancer Care® Program Inductees
Surgical Oncology
Eleftherios “Terry” Mamounas, MD, MPH
Orlando Health Cancer Institute
- Mamounas is medical director of the Comprehensive Breast Program at the University of Florida Health Cancer Institute at Orlando Health, professor of surgery at University of Central Florida College of Medicine, and clinical professor of clinical sciences at Florida State University College of Medicine.
- Currently, he is chair of the NRG Oncology Breast Committee and past chair of the Breast Committee at the National Surgical Adjuvant Breast and Bowel Project (NSABP).
- He was the lead author for subgroup analysis of the KATHERINE trial (NCT01772472), which showed that adjuvant trastuzumab emtansine (T-DM1; Kadcyla) induced clinical benefit across patient subgroups vs trastuzumab for patients with HER2-positive early breast cancer without increasing risk for central nervous system recurrence.
- Mamounas also led the NRG Oncology/NSABP B-42 trial (NCT00382070) establishing that, for women with postmenopausal breast cancer, extended letrozole treatment did not significantly improve disease-free survival following 5 years of aromatase inhibitor-based therapy.
- In a combined analysis of the 2 NSABP neoadjuvant trials that Mamounas led of patients with breast cancer treated with neoadjuvant chemotherapy, results showed that age, clinical tumor characteristics before chemotherapy, and pathologic nodal status/breast tumor response after chemotherapy can predict risk for locoregional recurrence and optimize adjuvant radiation use in these patients.
- Mamounas is a past member of the Susan G. Komen Scientific Advisory Board and has authored or coauthored more than 400 abstracts, manuscripts, and book chapters.
Home
SUPPORTED BY
